

Inhaling in CF?

Flexible

with the new eFlow[®]*rapid* nebuliser system.



Leading CF experts recommend¹

Basic therapy in CF

Patients are recommended to continue their existing treatment regimen while receiving advanced therapy



The next generation
eFlow[®]rapid
nebuliser system

Newly designed eBase® Controller for better hand- ling and more mobility



The new eBase® Controller does the trick

The eFlow®*rapid* nebuliser system stands for efficient, safe and fast inhalation treatment combined with even more advantages.

It's...



...More flexible

Higher mobility thanks to handy controller design and battery pack.



...More individual


Setting options for individual controller light and sound settings.



... Time-saving

Thanks to short nebulization times² (eFlow® Technology) and immediate switch-off at the end of inhalation.

What do patients say about the new eBase® Controller?



"I'm much more mobile now that the device runs on battery power and has a slimmer format." (man)

"I no longer have to be ashamed in front of my friends, the eBase no longer looks like a medical device." (child)



"With the individual light setting, I can see if the device is still running and my child is inhaling, even from a distance." (mother)



Quotes from a usability study conducted by PARI in Germany from July to December 2022 with 9 patients. Patients were able to test the devices for a period of 6 months. Study report can be requested from PARI.

Benefits for an effective therapy at a glance

What's NEW



More mobility thanks to new controller design



More individuality thanks to individual controller settings



Immediate controller switch-off at the end of inhalation

In addition to



Short inhalation times²



Light, small, silent & mobile



Display provides feedback




No age restriction



Study – Reduced stress³

² Naehrig S et al. Eur J Med Res 2011; 16(2): 63-6
³ Ball R et al. Pediatr Pulmonol 2006; 41: 330

One box offers all the content for the right and flexible use



Spare Parts and Accessories

Description	Item number
eFlow [®] rapid nebuliser handset (incl. aerosol head)	678G8222
eFlow [®] rapid Aerosol Head	678B2620
Mouthpiece	078G3601
Connection cord	178G6010
Hard shell carrying case	078E8010
PARI Filter valve set ^{a)}	041G0500
PARI SMARTMASK (adults) ^{a)}	041G0730
SMARTMASK Kids (children aged 2 and older) ^{a)}	078G5000
SMARTMASK Baby (babies weighing 2.5 kg and more) ^{a)}	078G5026
easycare cleaning aid for aerosol heads ^{a)}	078G6100
Power supply	078B7116

a) The availability of accessories may differ between countries/sales regions.

Technical data

Weight: controller and connection cord	210 g / 8 oz
Dimensions (LxWxH): controller (approx.)	16 x 7 x 2 cm / 6.3 x 2.8 x 0.8 in
Weight: nebuliser handset	55 g / 1.9 oz
Dimensions (LxWxH): nebuliser handset (approx.)	14.5 x 5.0 x 6.3 cm / 5.7 x 2 x 2.5 in
PARI power supply (REF 078B7116 for international power supply)	Input: 100 - 240 V, 50-60 Hz  Output: 5 V  Total power consumption < 3.5 Watt
Sound pressure level (nebuliser handset)	< 33 dB (A)

eFlow[®] rapid Performance Characteristics

Min. fill volume	2.0 ml
Max. fill volume	6.0 ml
MMAD ^{a)} (Mass Median Aerodynamic Diameter)	4.6 µm
GSD ^{a)} (Geometric Standard Deviation)	1.8
Respirable fraction ^{a)}	< 5 µm 55% < 2 µm 6.5% 2 - 5 µm 48.5%
Aerosol output ^{b)}	0.62 g
Aerosol output rate ^{b)}	0.5 g/min

Aerosol data according to ISO 27427; nebulised medium: Salbutamol 2.5 ml. Measured values may vary depending on the medication used.

Recommended fill volume: see package leaflet for the medication

a) Measurement with Next Generation Pharmaceutical Impactor (NGI) at 23 °C and 50% relative humidity. Inspiratory flow: 15 l/min.

b) Measurement with breathing simulator at 23 °C and 50% relative humidity. 500 ml breathing volume, breathing frequency 15 cycles/minute, sinusoidal breathing pattern, inhalation/exhalation ratio 1:1 (with adults, may vary in children).

For performance characteristics for a nebuliser handset specifically approved for and/or supplied with a drug refer to the information about the drug.

Transport/Storage (unpacked product, between uses)	
Temperature	-25 to 70 °C/-13 to 158 °F
Humidity	0% to 93%
Air Pressure	500 to 1060 hPa/7 to 15 PSI

Operating Conditions

Temperature	5 to 40 °C/41 to 104 °F
Relative Humidity (non-condensing)	15% to 93%
Air Pressure	700 to 1060 hPa/10 to 15 PSI

Batteries

PARI rechargeable battery-pack (NiMH)	3.6 V (nominal), 2000 mAh
Runtime	About 2 hours of continuous operation

Device Classification According to IEC 60601-1 & IEC 60601-1-2

Type of electric shock protection (power supply)	Protection Class II
Degree of protection from electric shock (nebuliser handset)	Type BF
Degree of protection against water ingress per IEC 60529 (controller)	IP 22
Degree of protection when in the presence of flammable mixtures	No protection
Operating mode	Continuous Operation
Environment	Home use & professional healthcare settings

Electromagnetic compatibility data is available in table form upon request from PARI or on the Internet at <https://www.pari.com/fileadmin/Electromagnetic-compatibility-4.pdf>.



Frequently Asked Questions



The most frequently asked questions about the eFlow®rapid nebuliser system are answered here.



Product information, incl. handling videos can be found here.



PARI Pharma GmbH
Moosstraße 3, 82319 Starnberg, GERMANY, Email: info@pari.de, Tel. +49 (0)8151 279 0, www.pari.com

CE 0123